SARS-CoV-2 induces human plasmacytoid predendritic cell diversification via UNC93B and IRAK4.

The Journal of Experimental Medicine
Fanny OnodiVassili Soumelis

Abstract

Several studies have analyzed antiviral immune pathways in late-stage severe COVID-19. However, the initial steps of SARS-CoV-2 antiviral immunity are poorly understood. Here we have isolated primary SARS-CoV-2 viral strains and studied their interaction with human plasmacytoid predendritic cells (pDCs), a key player in antiviral immunity. We show that pDCs are not productively infected by SARS-CoV-2. However, they efficiently diversified into activated P1-, P2-, and P3-pDC effector subsets in response to viral stimulation. They expressed CD80, CD86, CCR7, and OX40 ligand at levels similar to influenza virus-induced activation. They rapidly produced high levels of interferon-α, interferon-λ1, IL-6, IP-10, and IL-8. All major aspects of SARS-CoV-2-induced pDC activation were inhibited by hydroxychloroquine. Mechanistically, SARS-CoV-2-induced pDC activation critically depended on IRAK4 and UNC93B1, as established using pDC from genetically deficient patients. Overall, our data indicate that human pDC are efficiently activated by SARS-CoV-2 particles and may thus contribute to type I IFN-dependent immunity against SARS-CoV-2 infection.

References

Feb 28, 2002·Annual Review of Immunology·Pierre GuermonprezSebastian Amigorena
Dec 14, 2002·Human Immunology·Simon RothenfusserGunther Hartmann
Mar 15, 2003·Science·Capucine PicardJean-Laurent Casanova
Apr 12, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sue E Blackwell, Arthur M Krieg
Dec 7, 2005·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Masanori Abe, Angus W Thomson
Sep 16, 2006·Science·Armanda CasrougeJean-Laurent Casanova
Nov 4, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Angela DolganiucGyongyi Szabo
May 24, 2007·PloS One·Jennifer Hartt MeyersAnthony S Fauci
Sep 18, 2007·Science·Shen-Ying ZhangJean-Laurent Casanova
Jul 22, 2008·Nature Reviews. Immunology·Michel GillietYong-Jun Liu
Sep 14, 2010·Trends in Immunology·Ivan HirschDaniel Olive
Jan 12, 2011·Annual Review of Immunology·Jean-Laurent CasanovaLluis Quintana-Murci
Feb 9, 2012·Proceedings of the National Academy of Sciences of the United States of America·Luisa Cervantes-BarraganBoris Reizis
Sep 24, 2013·Archivum Immunologiae Et Therapiae Experimentalis·Josias Brito FrazãoAntonio Condino-Neto
Jan 21, 2014·Trends in Cell Biology·Bettina L Lee, Gregory M Barton
Jun 6, 2017·Trends in Immunology·Laura M SnellDavid G Brooks
Dec 6, 2017·Nature Immunology·Solana G AlculumbreVassili Soumelis
Apr 30, 2020·Nature Reviews. Immunology·Matthew Zirui TayLisa F P Ng
May 23, 2020·PLoS Pathogens·Daolin TangRui Kang
May 28, 2020·Nature Reviews. Immunology·Dhiraj AcharyaMichaela U Gack
Jun 24, 2020·Frontiers in Public Health·Raghuvir KeniKrishnadas Nandakumar
Jul 25, 2020·JAMA : the Journal of the American Medical Association·Caspar I van der MadeAlexander Hoischen
Sep 26, 2020·Science·Qian ZhangJean-Laurent Casanova
Sep 26, 2020·Science·Paul BastardJean-Laurent Casanova
Oct 11, 2020·Journal of Hepatology·Tarik AsselahRaymond F Schinazi

❮ Previous
Next ❯

Methods Mentioned

BETA
density gradient centrifugation
light microscopy
flow cytometry
PCR
ELISA

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.